The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta‐analysis
Abstract
BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The authors performed comprehensive meta‐analysis to assess the strength of associations between these conditions and the BRAFV600E mutation. METHODS: The authors identified the clinical studies that examined the association of the BRAFV600E mutation in surgical specimens with clinicopathologic outcomes between January 2003 and October 2010 using the Medline database. One hundred thirty‐one relevant studies were hand‐searched. The authors selected 27 studies that included 5655 PTC patients. They calculated the pooled odds ratios (ORs) or risk ratios with 95% confidence intervals (CIs) for each study using a random effect model. RESULTS: The average prevalence rate of the BRAFV600E mutation was 49.4%. In 26 studies, compared with the patients who had the wild‐type BRAF genes, the PTC patients with the BRAFV600E mutation had increased ORs of an extrathyroidal invasion (OR, 2.14; 95% CI, 1.68‐2.73), a lymph node metastasis (OR, 1.54; 95% CI, 1.21‐1.97), and an advanced TNM stage (OR, 2.00; 95% CI, 1.61‐2.49). In 8 studies, patients with the mutation had 2.14‐fold increased risk of recurrent and persistent disease (95% CI, 1.67‐2.74). The associations were generally consistent across the different study populations. CONCLUSIONS: This meta‐analysis demonstrates that the BRAFV600E mutation is closely related to the high‐risk clinicopathological factors and poorer outcome of PTC. The results obtained here suggest that the BRAFV600E mutation should be considered as a poor prognostic marker in PTC and may lead to better management for individual patients. Cancer 2012;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005
Chen, A. Y., Jemal, A., & Ward, E. M. (2009) · Cancer · doi:10.1002/cncr.24416 · Cited by 988
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Leboulleux, S., Rubino, C., Baudin, E., Caillou, B., Hartl, D. M., Bidart, J.-M., Travagli, J.-P., & Schlumberger, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0285 · Cited by 588
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Thyroid Cancer Epidemiology and Prognostic Variables
Sipos, J. A., & Mazzaferri, E. L. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.05.004 · Cited by 514
Adeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., & Nikiforov, Y. E. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176432.73455.1b · Cited by 495
The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., Shibru, D., Bastian, B., & Griffin, A. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148563d · Cited by 480
Zaydfudim, V., Feurer, I. D., Griffin, M. R., & Phay, J. E. (2008) · Surgery · doi:10.1016/j.surg.2008.08.034 · Cited by 453
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
National Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2707 · Cited by 397
Loh, K.-C. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3553 · Cited by 396
Lupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1179 · Cited by 391
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Lee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
Self-citationITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-208 · Cited by 255
BRAF(V600E) mutation and the biology of papillary thyroid cancer
Frasca, F., Nucera, C., Pellegriti, G., Gangemi, P., Attard, M., Stella, M., Loda, M., Vella, V, Giordano, C., Trimarchi, F., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0212 · Cited by 232
Kim, T. Y., Kim, W. B., Song, J. Y., Rhee, Y. S., Gong, G., Cho, Y. M., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02389.x · Cited by 221
Self-citationAssociation of High Iodine Intake with the T1799A BRAF Mutation in Papillary Thyroid Cancer
Guan, H., Ji, M., Bao, R., Yu, H., Wang, Y., Hou, P., Zhang, Y., Shan, Z., Teng, W., & Xing, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2390 · Cited by 218
Prognostic utility of BRAF mutation in papillary thyroid cancer
Xing, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.012 · Cited by 210
BRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
Knauf, J. A., Sartor, M. A., Medvedovic, M., Lundsmith, E., Ryder, M., Salzano, M., Nikiforov, Y. E., Giordano, T. J., Ghossein, R. A., & Fagin, J. A. (2011) · Oncogene · doi:10.1038/onc.2011.44 · Cited by 170
Abubaker, J., Jehan, Z., Bavi, P., Sultana, M., Al-Harbi, S., Ibrahim, M., Al-Nuaim, A., Ahmed, M., Amin, T., Al-Fehaily, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1717 · Cited by 169
B-Raf V600E and thrombospondin-1 promote thyroid cancer progression
Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 168
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation
Yip, L., Nikiforova, M. N., Carty, S. E., Yim, J. H., Stang, M. T., Tublin, M. J., LeBeau, S. O., Hodak, S. P., Ogilvie, J. B., & Nikiforov, Y. E. (2009) · Surgery · doi:10.1016/j.surg.2009.09.011 · Cited by 165
Jo, Y. S., Li, S., Song, J. H., Kwon, K. H., Lee, J. C., Rha, S. Y., Lee, H. J., Sul, J. Y., Kweon, G. R., Ro, H.-K., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2836 · Cited by 160
Oler, G., & Cerutti, J. M. (2009) · Cancer · doi:10.1002/cncr.24118 · Cited by 123
BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression
Nucera, C., Lawler, J., & Parangi, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3844 · Cited by 101
Nucera, C., Nehs, M. A., Nagarkatti, S. S., Sadow, P. M., Mekel, M., Fischer, A. H., Lin, P., Bollag, G. E., Lawler, J., Hodin, R. A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0317 · Cited by 91
Rivera, M., Ricarte‐Filho, J. C., Tuttle, R. M., Ganly, I., Shaha, A. R., Knauf, J. A., Fagin, J. A., & Ghossein, R. A. (2010) · Thyroid · doi:10.1089/thy.2010.0174 · Cited by 90
Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma
Kim, J., Giuliano, A. E., Turner, R. R., Gaffney, R., Umetani, N., Kitago, M., Elashoff, D. A., & Hoon, D. S. �. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224751.80858.13 · Cited by 79
Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis
Kim, K., Suh, K., Kang, D., & Kang, D. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01866.x · Cited by 71
Self-citationBRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.
Goutas, N. D., Vlachodimitropoulos, D. G., Bouka, M., et al. (2008) · PubMed · Cited by 69
Nakayama, H., Yoshida, A., Nakamura, Y., Hayashi, H., Miyagi, Y., Wada, N., Rino, Y., Masuda, M., & Imada, T. (2007) · PubMed · Cited by 63
BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas
Lee, J. H., Lee, E. S., Kim, Y., Won, N. H., & Chae, Y. (2006) · Pathology · doi:10.1080/00313020600696264 · Cited by 60
Self-citationWang, Y., Ji, M., Wang, W., Miao, Z., Hou, P., Chen, X., Xu, F., Zhu, G., Sun, X., Li, Y., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0182 · Cited by 46
Sýkorová, V., Dvořáková, Š., Ryška, A., Včelák, J., Václavíková, E., Laco, J., Kodetova, D. N., Kodet, R., Cibula, A., Duskova, J., et al. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346593 · Cited by 41
Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma
Musholt, T. J., Schönefeld, S., Schwarz, C. H., Watzka, F., Musholt, P. B., Fottner, C., Weber, M. M., Springer, E., & Schad, A. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0682-6 · Cited by 22
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Xing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Metadata
- Authors
- Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., Cho, B. Y., & Park, D. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-08-31
- Volume
- 118
- Issue
- 7
- Pages
- 1764-1773
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1538981488
- Cited by
- 400
- References
- 48
- FWCI
- 26.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.